Core Insights - Klotho Neurosciences, Inc. has terminated its Share Exchange Agreement with SkyBell Technologies, allowing the company to focus on its core R&D programs and enhance shareholder value [2][3] Company Overview - Klotho Neurosciences, Inc. is a biogenetics company specializing in innovative, disease-modifying cell and gene therapies derived from the anti-aging human Klotho gene, targeting neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease [4] Strategic Implications - The termination of the agreement eliminates the need to issue new common stock to SkyBell, which would have resulted in SkyBell owning 90% of Klotho, thereby preventing significant dilution of existing shareholders [7] - The company will not incur any liability as a result of this termination, allowing it to refocus its strategy and allocate resources towards advancing its primary therapeutic and longevity programs [7]
KLOTHO NEUROSCIENCES (KLTO) ANNOUNCES MUTUAL TERMINATION OF SHARE EXCHANGE AGREEMENT WITH SKYBELL TECHNOLOGIES (SKYBELL), TO CONTINUE ITS FOCUS ON THERAPEUTICS AND LONGEVITY PROGRAMS